Cerus Announces French Regulatory Approval of the INTERCEPT Blood System for Plasma.CONCORD, Calif. -- Cerus Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CERS) today announced that the French regulatory agency for medical products, the Agence Fran[?]aise de Securite Sanitaire des Produits de Sante (AFSSAPS AFSSAPS Agence Francaise de Securite Sanitaire des Produits de Sante ) has granted regulatory approval in France for use of plasma treated with the INTERCEPT Blood System, subject to official journal publication. Before the plasma system can be launched broadly in France, reimbursement pricing also needs to be established. "This approval marks a significant step towards commercializing our plasma system in France," said Claes Glassell, president and chief executive officer, Cerus Corporation. "We are pleased that the AFSSAPS approved the plasma system so quickly." ABOUT THE PLASMA SYSTEM The INTERCEPT Blood System for plasma is designed to provide increased protection to the blood supply from emerging pathogens, such as West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. and Chikungunya
The efficacy and safety of INTERCEPT plasma system was evaluated in transfusions comprising approximately 5,000 units. The plasma system is designed to meet blood center requirements for efficiency, performance and compatibility with both whole blood and apheresis apheresis (əfĕr`əsĭs), or hemapheresis (hē'məfĕr`əsĭs), any procedure in which blood is drawn from a donor or patient and a component (platelets, plasma, or white blood collections. Approximately 1.5 million plasma units for transfusion are collected annually in Europe. About 70% of those units undergo pathogen inactivation inactivation /in·ac·ti·va·tion/ (in-ak?ti-va´shun) the destruction of biological activity, as of a virus, by the action of heat or other agent. treatment or quarantine to meet European standards for plasma safety. ABOUT CERUS Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies . In the field of immunotherapy, the company is employing its proprietary attenuated Attenuated Alive but weakened; an attenuated microorganism can no longer produce disease. Mentioned in: Tuberculin Skin Test attenuated having undergone a process of attenuation. Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion